From Formulation Quality to Anti-Tumor Immunity: A Multimodal Imaging and Translational Framework for mRNA–Lipid Nanoparticle Cancer Vaccines in Preclinical Tumor Models
5 affiliations
- 1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan
- 2College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 72603, United Arab Emirates
- 3Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan
- 4Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan
- 5Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, P.O. Box 330127, Zarqa 13133, Jordan
Abstract
mRNA–Lipid nanoparticles (LNPs) for cancer vaccines are often considered a linear progression, in which formulation, biodistribution, innate stimulation, antigen expression, and tumor control form a continuum. They are not. This review connects the manufacturing inputs and lipid composition to particle attributes, innate sensing, organ and cell exposure, cytosolic translation, antigen presentation, therapeutic response, and hepatic safety. This review aims to provide a mechanism-aligned framework from critical quality attributes (CQAs) and critical process parameters (CPPs) to innate sensing, multimodal imaging, and preclinical efficacy and safety that can be used to design and interpret preclinical studies of mRNA-LNP cancer vaccines, with explicit attention to orthotopic pancreatic ductal adenocarcinoma (PDAC) models. Principal findings: (i) total organ signal is an inadequate surrogate for productive delivery; the decisive variable is translation of antigen in a permissive antigen-presenting cell (APC) during a defined inflammatory window; (ii) formulation and process variables including size, PDI, encapsulation, RNA integrity and capping, lipid composition, PEG-lipid architecture, mixing conditions, and storage history alter this conversion; and (iii) multimodal imaging is most informative when carrier or payload tracking is paired with reporter or antigen expression, immune profiling, tumor response, and liver-safety assays. We propose a release-to-response architecture for preclinical studies and identify the evidence required for clinically interpretable pharmacology. We reviewed peer-reviewed studies on mRNA cancer vaccination, quantitative imaging, PDAC models, LNP quality-by-design, and formulation-dependent innate immunology. The total organ signal is an inadequate surrogate for productive delivery; the decisive variable is translating antigen into an antigen-presenting cell during a permissive inflammatory window. Particle size, polydispersity, encapsulation, RNA integrity and capping, lipid composition, PEG-lipid architecture, mixing conditions, and storage history can alter this conversion. Multimodal imaging is most informative when carrier or payload tracking is paired with reporter or antigen expression, immune profiling, tumor response, and liver safety assays. PDAC studies have shown that hepatic or splenic exposure can be either a liability or intentional immune reprogramming. We propose a release-to-response architecture for preclinical studies and identify the evidence required for clinically interpretable pharmacology.
Related
- Beyond Efficacy: Preclinical Validation and Translational Readiness of Recent Multimodal Photodynamic Nanoplatforms for Glioblastoma
- RNA-encoded PGT121-LS anti-HIV antibody: Comprehensive preclinical characterization and translational pharmacokinetics
- Probiotic-hydrogel systems for microbiome-associated diseases: design principles, preclinical evidence, and translational challenges.
- Plant-derived nanovesicles in kidney disease: emerging preclinical evidence and translational challenges
- Gangliosides in Cutaneous Melanoma: Molecular Mechanisms, Translational Evidence Gaps, and Preclinical Natural-Compound Leads
BibTeX
@article{aljabali2026from,
title = {{From Formulation Quality to Anti-Tumor Immunity: A Multimodal Imaging and Translational Framework for mRNA–Lipid Nanoparticle Cancer Vaccines in Preclinical Tumor Models}},
author = {Alaa A. A. Aljabali and Mohammad A. Obeid and Abdelrahim Alqudah and Omar Gammoh and Esam Qnais},
journal = {Biomolecules},
year = {2026},
month = nov,
doi = {10.3390/biom16111589},
url = {https://www.mdpi.com/2218-273X/16/11/1589},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From Formulation Quality to Anti-Tumor Immunity: A Multimodal Imaging and Translational Framework for mRNA–Lipid Nanoparticle Cancer Vaccines in Preclinical Tumor Models
AU - Alaa A. A. Aljabali
AU - Mohammad A. Obeid
AU - Abdelrahim Alqudah
AU - Omar Gammoh
AU - Esam Qnais
PY - 2026
DA - 2026/11/01
JO - Biomolecules
DO - 10.3390/biom16111589
UR - https://www.mdpi.com/2218-273X/16/11/1589
AB - mRNA–Lipid nanoparticles (LNPs) for cancer vaccines are often considered a linear progression, in which formulation, biodistribution, innate stimulation, antigen expression, and tumor control form a continuum. They are not. This review connects the manufacturing inputs and lipid composition to particle attributes, innate sensing, organ and cell exposure, cytosolic translation, antigen presentation, therapeutic response, and hepatic safety. This review aims to provide a mechanism-aligned framework from critical quality attributes (CQAs) and critical process parameters (CPPs) to innate sensing, multimodal imaging, and preclinical efficacy and safety that can be used to design and interpret preclinical studies of mRNA-LNP cancer vaccines, with explicit attention to orthotopic pancreatic ductal adenocarcinoma (PDAC) models. Principal findings: (i) total organ signal is an inadequate surrogate for productive delivery; the decisive variable is translation of antigen in a permissive antigen-presenting cell (APC) during a defined inflammatory window; (ii) formulation and process variables including size, PDI, encapsulation, RNA integrity and capping, lipid composition, PEG-lipid architecture, mixing conditions, and storage history alter this conversion; and (iii) multimodal imaging is most informative when carrier or payload tracking is paired with reporter or antigen expression, immune profiling, tumor response, and liver-safety assays. We propose a release-to-response architecture for preclinical studies and identify the evidence required for clinically interpretable pharmacology. We reviewed peer-reviewed studies on mRNA cancer vaccination, quantitative imaging, PDAC models, LNP quality-by-design, and formulation-dependent innate immunology. The total organ signal is an inadequate surrogate for productive delivery; the decisive variable is translating antigen into an antigen-presenting cell during a permissive inflammatory window. Particle size, polydispersity, encapsulation, RNA integrity and capping, lipid composition, PEG-lipid architecture, mixing conditions, and storage history can alter this conversion. Multimodal imaging is most informative when carrier or payload tracking is paired with reporter or antigen expression, immune profiling, tumor response, and liver safety assays. PDAC studies have shown that hepatic or splenic exposure can be either a liability or intentional immune reprogramming. We propose a release-to-response architecture for preclinical studies and identify the evidence required for clinically interpretable pharmacology.
SN - 2218-273X
ER -